Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins.
Array Technologies is a manufacturing company that provides solar tracker solutions for companies and businesses.
Codiak Biosciences is developing exosomes, natural vesicles that mediate inter-cellular communication, as both a powerful therapeutic modality and an advanced diagnostic system.
Eargo makes direct-to-consumer hearing aids, allowing customers to access help for their hearing loss from their homes.
Jack Creek Investment Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
MINISO Group Holding Limited operates as a holding company. The Company, through its subsidiaries, retails home decor, small electronics, textile, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. MINISO Group Holding serves customers worldwide.
Opthea Limited operates as a biotechnology company. The Company develops therapies for diabetic macular edema, corneal neovascularization and transplantation, and dry eye disease. Opthea serves patients and healthcare providers in Australia.
Praxis Precision Medicines, Inc. operates as a clinical-stage genetic neuroscience company. The Company develops therapies for patients and families affected by complex and debilitating brain disorders. Praxis Precision Medicines serves patients in the United States
Spinal Elements Holdings, Inc. is a medical device company. The Company focuses on the design, development, and commercialization of products and technologies for spine surgery procedures. Spinal Elements Holdings serves customers worldwide.
Tarsus is a clinical-stage biopharmaceutical company headquartered in Irvine, California. Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.